PCSK9 Inhibitors: Current Status and Emerging Frontiers in Lipid Control
Source : https://pubmed.ncbi.nlm.nih.gov/37996219/
Among PCSK9 inhibitors, monoclonal antibodies represent a cornerstone. Many trials have showed their efficacy in reducing LDL-C and the risk for major adverse clinical events, revealing long-lasting effects, with special...
Monoclonal antibodies, gene silencing, binding peptides, and active immunization are among the innovative pharmacologic strategies being explored for PCSK9 inhibition.
Share
Health Economics of Detection and Treatment of Children With Familial Hypercholesterolemia: to Screen or Not to Screen Is No Longer the Question
Here, we review the recent literature on health economic outcomes for the detection and management of FH in children. Recent findings A targeted literature review identified eight studies evaluating detection...
Detection and management of HeFH in pediatric populations was cost effective, regardless of the age of the children.
Share
Association Between Dyslipidaemia and Dry Eye Disease: a Systematic Review and Meta-Analysis
Source : https://bmjopen.bmj.com/content/13/11/e069283.long
PubMed, Embase, Web of Science and Cochrane Library were systematically searched from January 2000 to December 2021. We included observational studies to assess the correlation of DED with meibomian gland...
A history of lipid-lowering drug use was positively correlated with a significantly increased risk of dry eye disease.
Share
Bempedoic Acid - How Will it Shape the Future Lipid-Lowering Landscape? Mode of Action, Evidence, and Clinical Use
Source : https://pubmed.ncbi.nlm.nih.gov/37989119/
Background Low density lipoproteins are now proven to be causal for atherosclerosis. Pharmacological treatment focuses on an increase of LDL receptors, particularly in the hepatocyte, which leads to uptake of...
BA alone and in combination with ezetimibe is excellent for the treatment of patients who are not at goal after either statin therapy or, if statins are not tolerated, after PCSK9-reducing therapy.
Share
Clinical Competence, Communication Ability and Adherence to Choosing Wisely Recommendations for Lipid Reducing Drug Use in Older Adults
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10662284
Although lipid-lowering drugs are not recommended for primary prevention in patients 75+, prevalence of use is high and there is unexplained variation in prescribing between physicians.
More clinically competent physicians were more likely to prescribe lipid-lowering drug for primary prevention but only to patients aged 75 years or older.
Share